18 articles for M Congreve
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
Heptares Therapeutics
Biophysical fragment screening of theß1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.
Heptares Therapeutics
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
TBA
Identification of novel adenosine A(2A) receptor antagonists by virtual screening.
Heptares Therapeutics
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.
Heptares Therapeutics
Progress in structure based drug design for G protein-coupled receptors.
Heptares Therapeutics
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Astex Therapeutics
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
Astrazeneca Pharmaceuticals
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
Sosei Heptares
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
Sosei Heptares
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Astex Therapeutics
Sulfoximine substituted quinazolines for pharmaceutical compositions
Evotec Internatonal
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
Heptares Therapeutics